Cited by 435Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and MutationsLung Cancer Research Studies

An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer

Ashworth, Allison B., Senan, Suresh, Palma, David A., Riquet, Marc, Ahn, Yong Chan, Ricardi, Umberto, Congedo, Maria T., Gomez, Daniel R. +8 more·2014·Clinical Lung Cancer

Abstract

Introduction/background An individual patient data metaanalysis was performed to determine clinical outcomes, and to propose a risk stratification system, related to the comprehensive treatment of patients with oligometastatic NSCLC.Materials and methods After a systematic review of the literature, data were obtained on 757 NSCLC patients with 1 to 5 synchronous or metachronous metastases treated with surgical metastectomy, stereotactic radiotherapy/radiosurgery, or radical external-beam radiotherapy, and curative treatment of the primary lung cancer, from hospitals worldwide. Factors predictive of overall survival (OS) and progression-free survival were evaluated using Cox regression. Risk groups were defined using recursive partitioning analysis (RPA). Analyses were conducted on training and validating sets (two-thirds and one-third of patients, respectively).Results Median OS was 26 months, 1-year OS 70.2%, and 5-year OS 29.4%. Surgery was the most commonly used treatment for the primary tumor (635 patients [83.9%]) and metastases (339 patients [62.3%]). Factors predictive of OS were: synchronous versus metachronous metastases (P < .001), N-stage (P = .002), and adenocarcinoma histology (P = .036); the model remained predictive in the validation set (c-statistic = 0.682). In RPA, 3 risk groups were identified: low-risk, metachronous metastases (5-year OS, 47.8%); intermediate risk, synchronous metastases and N0 disease (5-year OS, 36.2%); and high risk, synchronous metastases and N1/N2 disease (5-year OS, 13.8%).Conclusion Significant OS differences were observed in oligometastatic patients stratified according to type of metastatic presentation, and N status. Long-term survival is common in selected patients with metachronous oligometastases. We propose this risk classification scheme be used in guiding selection of patients for clinical trials of ablative treatment.

Integrity signals

Registry

Crossref · 10.1016/j.cllc.2014.04.003

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ashworth, A. B., Senan, S., Palma, D. A., Riquet, M., Ahn, Y. C., Ricardi, U., Congedo, M. T., Gomez, D. R., Wright, G. M., Melloni, G., Milano, M. T., Sole, C. V., De Pas, T. M., Carter, D. L., Warner, A. J., & Rodrigues, G. B.
Affiliations
  • London Health Sciences Centre (CA)
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
  • Hôpital Européen Georges-Pompidou (FR)
  • Samsung Medical Center (KR)
  • University of Turin (IT)
  • Università Cattolica del Sacro Cuore (IT)
  • The University of Texas MD Anderson Cancer Center (US)
  • The University of Melbourne (AU)
  • IRCCS Ospedale San Raffaele (IT)
  • University of Rochester Medicine (US)
  • Rocky Mountain Cancer Centers (US)
Venue
Clinical Lung Cancer
Publisher
Elsevier BV
Published
2014-09
Volume
15
Issue
5
Pages
346-355
ISSN
1525-7304 (ISSN-L)
OpenAlex
W1969531640
Cited by
435
References
56
Citations by year
2026: 11 · 2025: 20 · 2024: 29 · 2023: 39 · 2022: 56 · 2021: 49 · 2020: 44 · 2019: 49 · 2018: 42 · 2017: 32 · 2016: 30 · 2015: 26 · 2014: 8
FWCI
5.47
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Lung Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
oligometastatic non-small cell lung cancer, synchronous metastases, metachronous metastasis, risk stratification, prognostic factors, overall survival, progression-free survival, N stage, adenocarcinoma histology, stereotactic radiotherapy, external beam radiotherapy, recursive partitioning
MeSH terms
Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Metastasis, Prognosis, Risk, Survival Rate, Proportional Hazards Models, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review